Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.93 |
| ▸ | TP53 | P04637 | 1/20 | 0.93 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.93 |
| ▸ | P4HB | P07237 | 8/20 | 0.82 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2153404 | 0.96 | MAPT (1.00) | MAPTTP53SMN1; SMN2P4HBMDM2 | |
| SCHEMBL29632645 | 0.96 | MAPT (1.00) | MAPTTP53SMN1; SMN2P4HBMDM2 | |
| SCHEMBL13836063 | 0.95 | MAPT (0.91) | MAPTTP53SMN1; SMN2P4HBMDM2 | |
| SCHEMBL15783251 | 0.94 | MAPT (0.90) | MAPTTP53SMN1; SMN2P4HBMDM2 | |
| SCHEMBL13836595 | 0.92 | MAPT (0.85) | MAPTTP53SMN1; SMN2P4HBMDM2 | |
| SCHEMBL15783087 | 0.91 | P4HB (0.88) | MAPTTP53SMN1; SMN2P4HBMDM2 | |
| SCHEMBL15783112 | 0.90 | P4HB (0.86) | MAPTTP53SMN1; SMN2P4HBMDM2 | |
| SCHEMBL9965749 | 0.90 | P4HB (1.00) | MAPTTP53SMN1; SMN2P4HBMDM2 | |
| SCHEMBL18415246 | 0.86 | MAPT (0.82) | MAPTTP53SMN1; SMN2P4HBMDM2 | |
| SCHEMBL15783083 | 0.86 | MAPT (0.82) | MAPTTP53SMN1; SMN2P4HBMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190256471-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE AR (US) | 2019-08-22 | — | — | US | disclosed |
| US-10301265-B2 | Small molecule inhibitors of botulinum neurotoxins | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2019-05-28 | — | — | US | disclosed |
| US-9073858-B2 | Methods of targeted drug development | Errico, Joseph P. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20140194439-A1 | METHODS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20120295890-A1 | GLYCOSAMINOGLYCAN INHIBITORS | Zacharon Pharmaceutical, Inc. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110294848-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2011-12-01 | — | — | US | disclosed |
| US-20110294848-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2011-12-01 | — | — | US | disclosed |
| WO-2011082175-A2 | GLYCOSAMINOGLYCAN INHIBITORS | ZACHARON PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | MAPT 1076/4885TP53 230/4885SMN1; SMN2 3999/4885 |
| US-20120295890-A1 | GLYCOSAMINOGLYCAN INHIBITORS | CSGALNACT1, FUT5, ST3GAL3 | MAPT 4328/4885TP53 3840/4885SMN1; SMN2 4368/4885 |
| US-10301265-B2 | Small molecule inhibitors of botulinum neurotoxins | RAC2, BTN3A1, GDI1 | MAPT 2064/4885TP53 3978/4885SMN1; SMN2 2129/4885 |
| US-20190256471-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | RAC2, BTN3A1, GDI1 | MAPT 2064/4885TP53 3978/4885SMN1; SMN2 2129/4885 |
| US-20140194439-A1 | METHODS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB4 | MAPT 1499/4885TP53 192/4885SMN1; SMN2 4080/4885 |
| US-20110294848-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | RAC2, BTN3A1, GDI1 | MAPT 2064/4885TP53 3978/4885SMN1; SMN2 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.